Showing 991-1000 of 3366 results for "".
Developing PsA: Risk Factors for Psoriasis Patients
https://practicaldermatology.com/topics/psoriasis/developing-psa-risk-factors-for-psoriasis-patients/19651/Can patients with psoriasis lessen their chance of developing psoriatic arthritis? Ronald Prussick, MD discusses the known risk factors and the importance of weight and a low BMI for these patients. He also talks about non-alcoholic fatty liver syndrome in this patient population.Topical Toxins: Now and Later
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/topical-toxins-now-and-later/18768/Topical neurotoxins are in late-stage development, with the potential to offer "softer" results and reduction of fine wrinkles. But they may not be approved for another few years. In the meantime, micro channel delivery of toxins, such as with AquaGold, is an option. Joel Schlessinger, MD, founder oCurrents: Eczema
https://practicaldermatology.com/topics/atopic-dermatitis/currents-eczema-1/23743/DermWireTV: Epsolay Approval; See My Skin from Vaseline; Jori Launch; Novartis Grant for Farmworker Justice
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-epsolay-approval-see-my-skin-from-vaseline-jori-launch-novartis-grant-for-farmworker-justice/20094/Vaseline’s new See My Skin Campaign aims to help consumers of all skin types recognize skin diseases and connect them with dermatologists who can help manage them. Uchenna Okereke, MD discusses the initiative. Farmworker Justice, an organization dedicated to empowering farmworkers to improve immigraBehind the Pulse: Considerations for evaluating a picosecond laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/behind-the-pulse-considerations-for-evaluating-a-picosecond-laser/19749/If you are considering a picosecond system, this is the one webinar you will want to see. With content developed by Candela’s VP of Technology Research and Distinguished Fellow, Xiaoming Shang, PhD, along with a presentation by Perry Tomasetti, Candela’s Senior Director, Product Development, you wilHow Air Pollution Affects the Skin
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/how-air-pollution-affects-the-skin/20259/Mark Birch-Machin, PhD, a professor of molecular dermatology at New Castle University, talks about the effects that air pollution can have on skin. Dr. Birch-Machin also talks about a recent study his team published in FASEB BioAdvances looking at the effects of air pollution on human skin equivalenThe Challenges of Topical Steroid Withdrawal
https://practicaldermatology.com/topics/practice-management/the-challenges-of-topical-steroid-withdrawalogy/21118/Now more widely reported, topical steroid addiction should compel all prescribers to reflect on their use of topical corticosteroids.Hyperpigmentation Treatment Pearls and More
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/hyperpigmentation-treatment-pearls-and-more/20161/Corey Hartman, MD shares his approach to treating periorbital hyperpigmentation in darker skin types, including using fillers to replace volume, give lift, and replace loss of bony structures and fat pads. Dr. Hartman also discusses the benefits of Cynosure’s PicoSure device to correct hyperpigmentaDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PSkin Reactions: Understanding New Drug Adverse Effects
https://practicaldermatology.com/conferences/aad-summer-2021/skin-reactions-understanding-new-drug-adverse-effects/19975/In addition to needing to stay abreast of new drugs in dermatology, it's important for dermatologists to stay informed about new medications that come to market in general. Vinod Nambudiri, MD, MBA says there are often dermatology-related adverse events that need to be managed. He discusses new canc